School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

ImmunityBio, Inc. IBRX

Healthcare · Biotechnology

$10.51last close 2026-10-09 · market cap $11.14B · delayed data

Trailing returns

1M+30.40%
3M+18.49%
6M+40.51%
1Y+330.74%
5Y+19.30%

Basis: Adjusted daily closes.

What it does

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Open IBRX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies